US FDA approves Novartis's Ilaris for CAPS
This article was originally published in Scrip
Executive Summary
The US FDA has approved Novartis's IL-1β antagonist Ilaris (canakinumab) for adults and children who have the rare auto-inflammatory disease cryopyrin-associated periodic syndrome (CAPS). This marks the first-ever approval for Ilaris, an antibody therapy that is also under regulatory review in the EU and other markets.